The NEOPRISM-CRC clinical trial has revealed groundbreaking findings in the field of bowel cancer treatment. Patients with a specific type of bowel cancer, who received preoperative immunotherapy using the drug pembrolizumab, have shown remarkable durability in their response to treatment. After almost three years of follow-up, none of the treated patients have experienced a recurrence of their cancer, even those with small amounts of cancer remaining at the start of treatment.
This study, led by a team from UCL and UCLH, builds upon earlier results demonstrating major tumour shrinkage in patients with stage two or three bowel cancer after nine weeks of pre-operative immunotherapy. The latest findings, to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlight the potential of immunotherapy as a more effective and long-lasting treatment for this type of cancer compared to surgery and chemotherapy.
Dr. Kai-Keen Shiu, Chief Investigator of the trial, expresses optimism about the findings, stating that the absence of cancer recurrence after almost three years is extremely encouraging. He emphasizes the potential for personalized blood tests and immune profiling to predict treatment response, allowing for tailored approaches to patient care. This could mean that patients with a lower risk of disease progression may require less intensive therapy, while those at higher risk could benefit from additional treatment.
The trial's success is particularly significant given the prevalence of bowel cancer in the UK, with around 44,000 cases annually. While early detection significantly improves outcomes, specific sub-types of tumours don't respond well to treatment and are more likely to return. The NEOPRISM-CRC trial's findings suggest that preoperative immunotherapy may offer a more effective solution for these high-risk patients.
The study's personalized blood tests, designed to monitor treatment response and cancer presence, provide valuable insights into the treatment's effectiveness. Yanrong Jiang, the first author of the latest abstract, highlights the importance of these tests in guiding treatment decisions in a timely manner. The ability to predict treatment response early on could revolutionize patient care, ensuring that those at higher risk receive appropriate and intensive treatment.
Christopher Burston, a patient who participated in the trial, shares his positive experience. Diagnosed with stage 3 bowel cancer in 2023, he received preoperative immunotherapy followed by surgery. He experienced minimal side effects and has since returned to normal activities, cancer-free. His story exemplifies the potential of immunotherapy to provide durable responses and improve patients' quality of life.
In conclusion, the NEOPRISM-CRC trial's findings offer a glimmer of hope for patients with high-risk bowel cancer. The use of preoperative immunotherapy with pembrolizumab shows promise in providing long-lasting cancer control and improving outcomes. As research continues, the development of personalized blood tests and immune profiling may further enhance treatment strategies, offering a more precise and effective approach to managing this challenging cancer.
